People with hereditary angioedema (HAE) who have limited access to on-demand medications for swelling attacks are more likely to…
Articles by Michela Luciano, PhD
The U.S. Food and Drug Administration has accepted Pharvaris’ application seeking approval of the immediate-release (IR) formulation of…
A five-minute educational video designed to help healthcare professionals recognize and respond to life-threatening hereditary angioedema (HAE) attacks improved…
About 1 in 7 treated swelling attacks in people with hereditary angioedema (HAE) required an additional dose of on-demand…
An international registry collecting real-world data from people with recurrent angioedema — marked by repeated swelling episodes — has…
Long-term preventive treatment for hereditary angioedema (HAE) was associated with fewer swelling attacks requiring emergency or inpatient care, but…
Patients with hereditary angioedema (HAE) should ideally receive on-demand treatment within one hour of their first symptoms, according to…
Treatment with Xolair (omalizumab), an approved therapy for allergic asthma and chronic spontaneous urticaria (CSU), was associated with strong…
Children as young as 2 years may soon have access to the first-ever oral treatment for sudden hereditary angioedema…
Treatment with tranexamic acid does not appear to improve survival in people who develop angioedema after taking angiotensin-converting…